CCAL
KRYS icon

City Center Advisors LLC’s Krystal Biotech KRYS Stock Holding History

City Center Advisors LLC’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,628
Closed -$401K – 172
2025
Q4 		$401K Sell
1,628
-74
-4% -$15.6K 0.37% 82
2025
Q3 		$300K Buy
+1,702
New +$255K 0.29% 112

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

City Center Advisors LLC's KRYS Position: Q1 2026 in Review

City Center Advisors LLC sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 1,628 shares — an estimated $401K sold.

City Center Advisors LLC first reported a position in KRYS in Q3 2025 and held it in 2 quarters. The position peaked at $401K in Q4 2025. 368 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • City Center Advisors LLC reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • City Center Advisors LLC sold 1,628 Krystal Biotech shares in Q1 2026, an estimated $401K.
  • City Center Advisors LLC first reported a position in Krystal Biotech in Q3 2025 and held it in 2 quarters.
  • City Center Advisors LLC's Krystal Biotech position peaked at $401K in Q4 2025.
  • 368 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on City Center Advisors LLC's 13F filing for Q1 2026, filed 7 Apr 2026.